Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Surmeier
Uncategorized

Surmeier

By medwebFeb 27, 2008
Share
Facebook Twitter Email
D. James Surmeier, PhD

Senyei-Supported Study Leads to Progress in Parkinson’s Disease Treatment

In 2006, the newly established Drew Senyei, MD, Translational Research Awards supported four projects. The awards were made possible by a $1 million gift from Dr. Senyei, a 1979 medical school alumnus and Northwestern University Board of Trustees member, and exemplify Northwestern University’s commitment to “bench to bedside” research. One of the Senyei-awarded research studies is already offering hope for patients with Parkinson’s disease.

D. James Surmeier, PhD, Nathan Smith Davis Professor and chair of the Department of Physiology, Feinberg School of Medicine, is the principal investigator of a study exploring the use of a drug that may slow, and even halt, the progression of Parkinson’s disease. This movement disorder affects one million Americans. The drug, isradipine, rejuvenates aging dopamine cells, whose death in the brain causes symptoms that include rigidity, tremor, weakness, and loss of balance.

It has long been known that the symptoms of Parkinson’s disease result from the progressive death of neurons supplying the neurotransmitter dopamine. Dr. Surmeier and his team sought to understand why dopaminergic neurons, but not cortical pyramidal cells or other brain neurons, die. To do so, they looked at their electrical activity and re-discovered that dopaminergic neurons are calcium-dependent pacemakers. Pacemakers are cells that don’t need synaptic input to initiate action potential. “Cardiac cells are pacemakers,” Dr. Surmeier explains. “For example, your heart beats on its own without any external pacing.”

As sometimes happens in science, a fortunate series of events combined and provided new insight about these cells. Dr. Surmeier’s lab team obtained mice in which the gene coding for the calcium channel driving dopaminergic neuron pacemaking had been deleted. But the mice looked perfectly normal. Further recording showed that the dopaminergic cells in these animals were pacemaking in a normal way, indicating that the calcium channel was not absolutely necessary. “That observation led to experiments that showed that reliance on calcium ion channels was developmentally regulated,” Dr. Surmeier says. “Younger neurons used sodium ion channels. As they grew older, they relied more and more on calcium. That pointed us toward a potential therapy. We wondered, if we could block the calcium channel pharmacologically, would the dopaminergic neurons revert to their juvenile phenotype? Sure enough, that’s what they did.”

The calcium channels used in dopaminergic neurons are members of the L-type channel class, and dihydropyridine drugs that block these channels are commonly used to treat hypertension. Dr. Surmeier used one of these drugs, isradipine, and in both in vitro and in vivo experiments it caused dopaminergic neurons to revert to sodium channel pacemaking. “This made them resistant to the three toxins used to induce Parkinsonism in animal models,” he explains.

Dr. Surmeier notes that since isradipine has been used safely in humans for decades, it made sense to translate this discovery into clinical practice. He turned to Senyei award co-investigators, John Kessler, MD, Ken and Ruth Davee Professor of Stem Cell Biology and chair, Ken and Ruth Davee Department of Neurology and Neurological Sciences, and Tanya Simuni, MD, associate professor of neurology in the Department. They have initiated a clinical trial with early-stage Parkinson’s disease patients to determine whether they tolerate isradipine treatment and, with safety data from this trial, will apply to the National Institutes of Health to fund a larger study. Another member of the Senyei award research team, Richard B. Silverman, PhD, John Evans Professor of Chemistry, Weinberg College of Arts and Sciences, and member of the Center for Drug Discovery and Chemical Biology, has joined with Dr. Surmeier in screening compounds to identity a more selective antagonist for the brain channel.

“This work is an excellent example of how our scientists and clinicians are working together to maximize the impact of translational research,” says Jonathan Leis, PhD, professor of microbiology-immunology and senior associate dean for research. “We believe a drug like isradipine has the potential to slow or stop the progression of Parkinson’s symptoms,” says Dr. Surmeier. “If given early enough, it might even prevent the development of this disease.”

Written by: Gina Pryma

Share. Facebook Twitter Email

Related Posts

Mar 29, 2023

Adolescent Sexual Health Program Receives Funding for Social Marketing Campaign

Mar 29, 2023

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Comments are closed.

Latest News

Feinberg Investigators Identify How a Residential Neighborhood Can Impact Health

Sep 22, 2023

Robert Lamb, Renowned Expert on Influenza Virus, Dies at 72

Sep 22, 2023

Bethany Ekesa, Associate Director of SPARC, Honored with Jean E. Shedd University Citizenship Award

Sep 21, 2023

Combination Immunotherapy Shows No Additional Benefit for Most Advanced Cancers

Sep 21, 2023

Novel Intracellular Signaling Mechanisms Promote Melanoma Growth

Sep 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230914_NM461
20230914_NM644
20230914_NM345
20230914_NM444
20230914_NM464
20230914_NM520
20230914_NM673
20230914_NM641
20230914_NM612
20230914_NM608
20230914_NM602
20230914_NM597

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.